Search Results - "Jorgensen, Andrea L."

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review by Antoniou, Miranta, Jorgensen, Andrea L, Kolamunnage-Dona, Ruwanthi

“…Personalized medicine is a growing area of research which aims to tailor the treatment given to a patient according to one or more personal characteristics…”
Get full text

Warfarin dosing algorithms: A systematic review by Asiimwe, Innocent G., Zhang, Eunice J., Osanlou, Rostam, Jorgensen, Andrea L., Pirmohamed, Munir

“…Aims Numerous algorithms have been developed to guide warfarin dosing and improve clinical outcomes. We reviewed the algorithms available for various…”
Get full text

A Randomized Trial of Genotype-Guided Dosing of Warfarin by Pirmohamed, Munir, Burnside, Girvan, Eriksson, Niclas, Jorgensen, Andrea L, Toh, Cheng Hock, Nicholson, Toby, Kesteven, Patrick, Christersson, Christina, Wahlström, Bengt, Stafberg, Christina, Zhang, J. Eunice, Leathart, Julian B, Kohnke, Hugo, Maitland-van der Zee, Anke H, Williamson, Paula R, Daly, Ann K, Avery, Peter, Kamali, Farhad, Wadelius, Mia

“…This trial compared genotype-guided dosing with standard dosing in patients with atrial fibrillation or venous thromboembolism initiating warfarin…”
Get full text

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis by Jorgensen, Andrea L, FitzGerald, Richard J, Oyee, James, Pirmohamed, Munir, Williamson, Paula R

“…Warfarin is a highly effective anticoagulant however its effectiveness relies on maintaining INR in therapeutic range. Finding the correct dose is difficult…”
Get full text

STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline by Chaplin, Marty, Kirkham, Jamie J., Dwan, Kerry, Sloan, Derek J., Davies, Geraint, Jorgensen, Andrea L.

“…[...]large sample sizes are typically required to detect pharmacogenetic associations. Marty Chaplin (researcher into meta-analysis of pharmacogenetic…”
Get full text

Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study by Jorgensen, Andrea L, Prince, Clare, Fitzgerald, Gail, Hanson, Anita, Downing, Jennifer, Reynolds, Julia, Zhang, J Eunice, Alfirevic, Ana, Pirmohamed, Munir

“…Warfarin is a widely used oral anticoagulant. Determining the correct dose required to maintain the international normalised ratio (INR) within a therapeutic…”
Get full text

Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population by Carr, Daniel F., Chaponda, Mas, Jorgensen, Andrea L., Castro, Elena Cornejo, van Oosterhout, Joep J., Khoo, Saye H., Lalloo, David G., Heyderman, Robert S., Alfirevic, Ana, Pirmohamed, Munir

“…Background. The nonnucleoside reverse transcriptase inhibitor nevirapine is the cornerstone of treatment for human immunodeficiency virus (HIV) in many…”
Get full text

SurvivalGWAS_SV: software for the analysis of genome-wide association studies of imputed genotypes with "time-to-event" outcomes by Syed, Hamzah, Jorgensen, Andrea L, Morris, Andrew P

“…Analysis of genome-wide association studies (GWAS) with "time to event" outcomes have become increasingly popular, predominantly in the context of…”
Get full text

A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients by Asiimwe, Innocent G., Blockman, Marc, Cohen, Karen, Cupido, Clint, Hutchinson, Claire, Jacobson, Barry, Lamorde, Mohammed, Morgan, Jennie, Mouton, Johannes P., Nakagaayi, Doreen, Okello, Emmy, Schapkaitz, Elise, Sekaggya-Wiltshire, Christine, Semakula, Jerome R., Waitt, Catriona, Zhang, Eunice J., Jorgensen, Andrea L., Pirmohamed, Munir

“…Diversity in pharmacogenomic studies is poor, especially in relation to the inclusion of black African patients. Lack of funding and difficulties in…”
Get full text

Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease by Ho, Brian, Thompson, Andrew, Jorgensen, Andrea L, Pirmohamed, Munir

“…Population screening for non-alcoholic fatty liver disease (NAFLD) and associated comorbidities remains an unaddressed clinical need. We aimed to assess the…”
Get full text

Methodological quality of pharmacogenetic studies: Issues of concern by Jorgensen, Andrea L., Williamson, Paula R.

“…Pharmacogenetic studies investigate association between genetic variants‡ and drug efficacy and toxicity. Regardless of the extent of current knowledge…”
Get full text

Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck by Carter, Rachel J., Milani, Mateus, Butterworth, Michael, Alotibi, Ahoud, Harper, Nicholas, Yedida, Govindaraju, Greaves, Georgia, Al-Zebeeby, Aoula, Jorgensen, Andrea L., Schache, Andrew G., Risk, Janet M., Shaw, Richard J., Jones, Terry M., Sacco, Joseph J., Hurlstone, Adam, Cohen, Gerald M., Varadarajan, Shankar

“…Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide, with overall survival of less than 50%. Current therapeutic…”
Get full text

Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm by Asiimwe, Innocent G., Blockman, Marc, Cohen, Karen, Cupido, Clint, Hutchinson, Claire, Jacobson, Barry, Lamorde, Mohammed, Morgan, Jennie, Mouton, Johannes P., Nakagaayi, Doreen, Okello, Emmy, Schapkaitz, Elise, Sekaggya‐Wiltshire, Christine, Semakula, Jerome R., Waitt, Catriona, Zhang, Eunice J., Jorgensen, Andrea L., Pirmohamed, Munir

“…Warfarin remains the most widely prescribed oral anticoagulant in sub‐Saharan Africa. However, because of its narrow therapeutic index, dosing can be…”
Get full text

CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis by Richardson, Marty, Kirkham, Jamie, Dwan, Kerry, Sloan, Derek J, Davies, Geraint, Jorgensen, Andrea L

“…Treatment with anti-tuberculosis drugs may cause patients to experience serious adverse effects. Genetic factors, such as polymorphisms of CYP genes, may…”
Get full text

Effect of Genetic Variability in the CYP4F2 , CYP4F11 , and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response by Zhang, J E, Klein, Kathrin, Jorgensen, Andrea L, Francis, Ben, Alfirevic, Ana, Bourgeois, Stephane, Deloukas, Panagiotis, Zanger, Ulrich M, Pirmohamed, Munir

“…Genetic polymorphisms in the gene encoding cytochrome P450 (CYP) 4F2, a vitamin K oxidase, affect stable warfarin dose requirements and time to therapeutic…”
Get full text

Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration by Bourgeois, Stephane, Carr, Daniel F., Musumba, Crispin O., Penrose, Alexander, Esume, Celestine, Morris, Andrew P., Jorgensen, Andrea L., Zhang, J. Eunice, Pritchard, D. Mark, Deloukas, Panos, Pirmohamed, Munir

“…Low-dose aspirin can cause gastric and duodenal ulceration, hereafter called peptic ulcer disease (PUD). Predisposition is thought to be related to clinical…”
Get full text

A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study by Jorgensen, Andrea L, Orrell, Catherine, Waitt, Catriona, Toh, Cheng-Hock, Sekaggya-Wiltshire, Christine, Hughes, Dyfrig A, Allen, Elizabeth, Okello, Emmy, Tatz, Gayle, Culeddu, Giovanna, Asiimwe, Innocent G, Semakula, Jerome Roy, Mouton, Johannes P, Cohen, Karen, Blockman, Marc, Lamorde, Mohammed, Pirmohamed, Munir

“…The quality of warfarin anticoagulation among Sub-Saharan African patients is suboptimal. This is due to several factors, including a lack of standardized…”
Get full text

Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome by Turner, Richard M., MB BChir, Yin, Peng, PhD, Hanson, Anita, BSc, FitzGerald, Richard, MB ChB, Morris, Andrew P., PhD, Stables, Rod H., DM, Jorgensen, Andrea L., PhD, Pirmohamed, Munir, PhD

“…Background High-potency statin therapy is recommended in the secondary prevention of cardiovascular disease but discontinuation, dose reduction, statin…”
Get full text

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy by Zhang, Jieying Eunice, Jorgensen, Andrea L, Alfirevic, Ana, Williamson, Paula R, Toh, Cheng H, Park, Brian Kevin, Pirmohamed, Munir

“…BACKGROUNDA variant in the CYP4F2 gene, rs2108622, has been recently shown to determine stable warfarin dose requirements. CYP4F2 has also been shown recently…”
Get full text

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study by Jorgensen, Andrea L, Al-Zubiedi, Sameh, Zhang, Jieying Eunice, Keniry, Andrew, Hanson, Anita, Hughes, Dyfrig A, Eker, Diane van, Stevens, Lisa, Hawkins, Karen, Toh, Cheng H, Kamali, Farhad, Daly, Ann K, Fitzmaurice, David, Coffey, Alison, Williamson, Paula R, Park, Brian Kevin, Deloukas, Panos, Pirmohamed, Munir

“…BACKGROUNDIn this prospective cohort study, we have undertaken a comprehensive evaluation of clinical parameters along with variation in 29 genes (including…”
Get full text